Diagnosis and Treatment of Male Penile Discharge
Diagnostic Confirmation
- A sexually active male presenting with penile discharge should be treated empirically with ceftriaxone 250 mg IM plus doxycycline 100 mg orally twice daily for 7 days to cover both gonorrhea and chlamydia, as these are the two primary bacterial pathogens responsible for urethritis, according to the Centers for Disease Control and Prevention (CDC) 1
- Mucopurulent or purulent discharge is a diagnostic criterion for urethritis 1
- A Gram stain showing ≥5 polymorphonuclear leukocytes per oil immersion field in urethral secretions is a diagnostic criterion for urethritis, as recommended by the CDC 1, 2
- Obtain nucleic acid amplification tests (NAAT) for both N. gonorrhoeae and C. trachomatis on first-void urine or urethral swab, as these tests have sensitivities of 86.1%-100% and specificities of 97.1%-100%, according to the CDC 1
First-Line Empiric Treatment
- The CDC recommends ceftriaxone 250 mg IM single dose plus doxycycline 100 mg orally twice daily for 7 days as the first-line empiric treatment for gonorrhea and chlamydia 1, 3
- This combination addresses the two most important bacterial pathogens and prevents complications including epididymitis, Reiter's syndrome, and transmission to partners, according to the CDC 1, 2
Alternative Regimens
- Erythromycin base 500 mg orally 4 times daily for 7 days is an alternative regimen for chlamydia coverage, as recommended by the CDC 2
- Erythromycin ethylsuccinate 800 mg orally 4 times daily for 7 days is an alternative regimen for chlamydia coverage, as recommended by the CDC 2
Additional Testing Requirements
- The CDC recommends syphilis serology (sequential treponemal and nontreponemal antibody testing) for all patients with urethral discharge 4
- HIV counseling and testing are recommended for all patients with urethral discharge, according to the CDC 4
Partner Management
- Sexual partners from the 60 days preceding symptom onset must be referred for evaluation and treatment, as recommended by the CDC and the American College of Physicians 3, 4
- Patients should abstain from sexual intercourse until both they and their partners complete treatment and are symptom-free, according to the CDC 4
Follow-Up Protocol
- Patients must return for reevaluation if symptoms persist or recur after completing therapy, as recommended by the CDC and the American Academy of Family Physicians 2, 3
- For persistent or recurrent urethritis, re-treat with the initial regimen if non-compliant or re-exposed to untreated partner, according to the CDC 2